Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01899989 |
Recruitment Status :
Active, not recruiting
First Posted : July 16, 2013
Last Update Posted : November 18, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer | Radiation: Stereotactic Body Radiation Therapy (SBRT) Drug: cisplatin or carboplatin-based | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 39 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer |
Study Start Date : | July 5, 2013 |
Estimated Primary Completion Date : | July 2022 |
Estimated Study Completion Date : | July 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: A) >5cm,Chemo eligible (closed to accrual)
Patients will receive five fractions of either 8, 10, or 12 Gy to the gross tumor only. Following SBRT patients will be evaluated by their medical oncologist for consideration of adjuvant chemotherapy, starting 6-8 weeks post-RT. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy by their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year.
|
Radiation: Stereotactic Body Radiation Therapy (SBRT) Drug: cisplatin or carboplatin-based Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist. |
Experimental: B) 3-5cm OR Chemo ineligible
Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in < 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in < 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
|
Radiation: Stereotactic Body Radiation Therapy (SBRT) |
- maximum tolerated dose (Cohort A) [ Time Frame: 2 years ]standard 3+3 dose-escalation scheme
- ≥ grade 4 or persistent ≥ grade 3 late toxicities (Cohorts A & B) [ Time Frame: ≥3 months post SBRT ]All patients will be assessed for toxicities according to CTCAE v 4.0 at least once during SBRT.
- overall survival (Cohorts A & B) [ Time Frame: 2 years ]Response and progression will be evaluated per standard of care for radiographic progression on CT scans.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
All patients:
- Histologically confirmed non-small cell lung cancer
- Medically or technically inoperable as per thoracic surgeon or patient's preference not to undergo surgical resection
- Age ≥ 18 years
- Women of childbearing potential must have a negative blood pregnancy test
- Ability to provide written informed consent
Cohort A:
- Stage IIA-IIIA (TanyN1M0 or T2b-4N0M0) Selected patients with single station N2 nodal involvement in close proximity to the primary tumor target may be considered eligible at the discretion of the PI if all normal tissue guidelines can be met
- Eligible for chemo-therapy
- Karnofsky Performance Status ≥70%
- Men and women of childbearing potential must be willing to use effective contraception while on treatment and for at least 3 months thereafter
-
Patients must show adequate organ function as defined by:
- Calculated creatinine clearance ≥40 mL/min for patients receiving pemetrexed (by Cockcroft-Gault)
- Calculated creatinine clearance ≥30 mL/min for patients receiving gemcitabine or paclitaxel (by Cockcroft-Gault) Total bilirubin less than 1.5 x ULN (unless known Gilbert's disease)
- AST and ALT less than 3 x ULN
- Absolute neutrophil count greater than 1500/mm3
- Platelet count greater than 100,000/mm3
Cohort B:
- T2a-4N0M0 who are not candidates for cohort A or who will not be treated with chemotherapy (due to patient preference or at the recommendation of the treating physician).
Exclusion Criteria:
All patients:
- Prior radiation therapy to the lungs
- Prior surgery or chemotherapy for this presentation of lung cancer (history of prior lung cancer that has been treated and deemed inactive by the clinician is acceptable. Recurrent tumors may be treated on protocol as long as SBRT will be the definitive treatment.)
- N2-3 lymph node involvement based on PET/EBUS-FNA/mediastinoscopy (Any N2 disease that is more than just minimal single station involvement is excluded)
- Direct tumor extension into including aorta or pulmonary artery
- Chronic corticosteroid use equivalent to ≥ prednisone 10 mg daily
Prior treatment with a CD137 agonist, ipilimumab, or the CTLA-4 inhibitor, or PD-1/PDL-1 inhibitor
- Unstable congestive heart failure
Cohort A:
- Continuous oxygen use
Patients meeting the following exclusion criteria will be excluded from the functional MRI portion only:
- Metallic implant,exclusions will be determined per institutional policies
- Pacemaker and defibrillators are excluded
- Stents etc. will be evaluated according to MSKCC policy
- Unmanageable claustrophobia
- High risk for nephrogenic systemic fibrosis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01899989
United States, New Jersey | |
Memorial Sloan Kettering Cancer Center at Basking Ridge | |
Basking Ridge, New Jersey, United States, 07920 | |
Memorial Sloan Kettering Monmouth | |
Middletown, New Jersey, United States, 07748 | |
Memorial Sloan Kettering Bergen | |
Montvale, New Jersey, United States, 07645 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center @ Suffolk | |
Commack, New York, United States, 11725 | |
Memorial Sloan Kettering Westchester | |
Harrison, New York, United States, 10604 | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
Memorial Sloan Kettering at Mercy Medical Center | |
Rockville Centre, New York, United States | |
Memorial Sloan Kettering Nassau | |
Uniondale, New York, United States, 11553 |
Principal Investigator: | Andreas Rimner, MD | Memorial Sloan Kettering Cancer Center |
Responsible Party: | Memorial Sloan Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT01899989 |
Other Study ID Numbers: |
13-113 |
First Posted: | July 16, 2013 Key Record Dates |
Last Update Posted: | November 18, 2021 |
Last Verified: | November 2021 |
Stereotactic Body Radiation Therapy (SBRT) Chemotherapy 13-113 |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms |
Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Carboplatin Antineoplastic Agents |